Participant flow

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies · Source last updated 2026-05-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   All participants in this study received both study drugs and were therefore analysed together as a single treatment arm. Participants receiving the different regimens were not analysed separately by regimen, as the study was designed to assess the safety of the combination study treatment. The study included N=161 participants who received both acalabrutinib and pembrolizumab and are summarized together (from First stage safety lead-in and Second stage expansion). Stage 3 (additional expansion in subjects with Myelofibrosis) was planned but not conducted.

   id

   FG000

   title

   Acalabrutinib + Pembrolizumab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         67

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Lost to Follow-up

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         10

      type

      Subject started another cancer therapy

   6. reasons

      1. group Id

         FG000

         num Subjects

         45

      type

      Study terminated by sponsor

   7. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Decision by subject not related to AE/SAE

   8. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Decision by PI not related to AE/SAE

   9. reasons

      1. group Id

         FG000

         num Subjects

         11

      type

      Disease progression

   10. reasons

       1. group Id

          FG000

          num Subjects

          20

       type

       Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         161

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         161

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

For the ACE-LY-005 program, Study Terminated by Sponsor refers to the following: Patients receiving treatment benefits will continue to be provided with study medication in the Post Final Analysis Management of the trial. No further data collection for analysis and reporting will be completed after the final Analysis

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice